PC3 / PC3-luc Orthotopic Mouse Model Service for Prostate Cancer

The PC3 / PC3-luc orthotopic mouse model for prostate cancer is an androgen-independent, AR-negative human xenograft platform in which highly metastatic PC3 cells are grafted into the prostate of immunodeficient mice, enabling organ-confined tumor growth together with spontaneous spread to regional lymph nodes, lung, and bone. Alfa Cytology supplies this model as an end-to-end preclinical capability — including authenticated PC3 / PC3-luc expansion and luciferase-stable banking, surgical orthotopic implantation or surgical orthotopic implantation of intact tumor fragments, scheduled in vivo bioluminescence surveillance of primary and metastatic lesions, and complete necropsy-based histopathology — all engineered around each sponsor’s compound, schedule, and endpoint blueprint.

Overview of PC3 / PC3-luc Orthotopic Mouse Model for Prostate Cancer

PC3 stands apart from other prostate cancer lines as a model of the fully androgen-independent, AR-null state of advanced disease. The line was established in 1979 by Kaighn and colleagues from a lumbar vertebral bone metastasis of a grade IV prostatic adenocarcinoma resected from a 62-year-old donor, and it has since become the reference line for late-stage, hormone-refractory biology. PC3 carries no detectable androgen receptor or PSA expression, is unresponsive to androgens, glucocorticoids, and EGF/FGF stimulation in vitro, harbors PTEN loss, and is near-triploid with a modal count of 62 chromosomes and no Y chromosome. It is also one of the most aggressively growing prostate lines in culture and in animals, displays high EGFR and TGF-α expression, expresses neuroendocrine markers such as CD44, NSE, and chromogranin A, and shows the highest metastatic potential among the classic prostate cancer panel — exceeding DU145 and far surpassing LNCaP.

Fig 1. Weekly bioluminescence imaging of orthotopic PC3-luc/EV vs PC3-luc/SPARCL1 tumors, whole-body luminescence index, and H&E/GFP-IHC of prostate, liver/pancreas, spleen, kidney and adrenal metastases with Kaplan-Meier survival. (Xiang, Yuzhu, et al., 2013)

Orthotopic grafting of PC3 unlocks this metastatic program: unlike flank xenografts, which rarely disseminate, tumors implanted into the dorsal or dorsolateral prostate lobes invade locally and seed regional lymph nodes and lung at high frequency, and surgical orthotopic implantation (SOI) of intact tumor fragments — which preserves stromal architecture — reproducibly yields the widespread pulmonary and lymphatic metastasis that cell-suspension models often require extensive selection to achieve. The PC3-luc derivative, stably transduced with firefly luciferase, makes every stage of this cascade measurable: tumor take, primary growth, and the emergence of distant lesions can be followed non-invasively by in vivo bioluminescence after luciferin administration, with ex vivo organ imaging at necropsy confirming metastatic distribution. This combination of rapid growth, robust spontaneous metastasis, and quantitative imaging makes the PC3 / PC3-luc orthotopic model a workhorse for anti-metastatic agent evaluation, bone-targeting therapies, neuroendocrine prostate cancer studies, and mechanistic work on invasion and dissemination.

Cell Line Information: PC3 / PC3-luc

The table below consolidates the defining biological and modeling features of the PC3 parental line and its luciferase-labeled derivative PC3-luc. Both are human-derived and require immunodeficient hosts for in vivo work.

Our Services

For teams pursuing late-stage, hormone-refractory prostate cancer biology, Alfa Cytology delivers the PC3 / PC3-luc orthotopic model as a single accountable program — validated cell banks, microsurgical grafting with either cell suspension or intact-fragment SOI, disciplined in vivo imaging schedules, and metastasis-focused endpoint pathology — all documented to preclinical quality standards and paced to each sponsor’s decision points.

Workflow of PC3 / PC3-luc Orthotopic Mouse Model Construction

Construction follows established orthotopic xenograft methodology: luciferase-labeled PC3 cells are expanded under authenticated conditions, formulated in a Matrigel- or collagen-supported suspension (or prepared as intact tumor fragments for SOI), grafted into the prostate of immunodeficient mice, and followed by serial imaging and metastasis-oriented endpoint analysis. The workflow comprises the following stages.

1. Cell authentication and banking: PC3 or PC3-luc cells are verified by STR profiling, confirmed mycoplasma-free, and expanded into low-passage working banks under standardized F-12K culture conditions.
2. Cell harvest and formulation: Subconfluent cultures are trypsinized, washed, counted and viability-checked, then resuspended in serum-free medium mixed 1:1 with cold Matrigel or neutralized type I collagen at the study-specified dose (commonly 1 × 10⁵–2 × 10⁶ cells per 10–30 μL) and kept on ice until implantation.
3. Anesthesia and surgical exposure: Male immunodeficient mice are anesthetized with isoflurane (or ketamine/xylazine where protocol-specified); a lower abdominal incision externalizes the bladder and seminal vesicle, exposing the dorsal or dorsolateral prostate lobe for inoculation.
4. Orthotopic implantation: The cell suspension is slowly injected into the prostate lobe using a fine-gauge needle (or small intact tumor fragments are grafted for the SOI variant); the needle is held briefly after injection so the matrix partially sets, limiting reflux and equalizing take rates.
5. Closure and perioperative care: The prostate is repositioned, the abdominal wall and skin are sutured, and animals receive analgesia with monitored recovery according to institutional guidelines.
6. Engraftment confirmation and serial imaging: Luciferin is administered intraperitoneally and bioluminescence is acquired to confirm tumor take and normalize group allocation; imaging repeats on a weekly cadence to quantify primary growth and flag emerging metastatic signal.
7. Intervention and endpoint analysis: Experimental arms — chemotherapy, targeted agents, anti-metastatic or bone-targeting compounds, and combination regimens — proceed per study design; endpoints integrate caliper and imaging measurements with necropsy, ex vivo organ bioluminescence to map metastatic distribution, and histopathology (H&E with Ki67 and marker-specific immunohistochemistry) of primary tumor, lymph nodes, lung, liver, and bone.

Fig 2. PC3 / PC3-luc orthotopic mouse model construction workflow.

Case Study-PC3 / PC3-luc Orthotopic Mouse Model Development

Alfa Cytology has applied the PC3 / PC3-luc orthotopic platform across preclinical programs targeting metastatic dissemination, bone lesion development, and hormone-refractory tumor growth. In these studies, orthotopically grafted PC3-luc tumors were followed by serial in vivo bioluminescence, with ex vivo organ imaging and histopathological confirmation of primary and metastatic disease delivered at endpoint. Program-level results and imaging datasets are available on request.

Why Choose Alfa Cytology?

Alfa Cytology combines demonstrated mastery of aggressive, metastasis-prone xenografts with integrated imaging and pathology capabilities, so each PC3 / PC3-luc orthotopic study is run with tight experimental control and reporting quality that sponsors can rely on.

• Proven expertise with androgen-independent, AR-negative models and metastasis-forward study designs, including SOI fragment grafting.
• Unified surgical, in vivo imaging, and pathology teams working under a single quality framework from cell bank to final report.
• Quantitative longitudinal bioluminescence readouts covering both primary tumor dynamics and early metastatic emergence.
• Flexible dosing and combination architectures matched to anti-metastatic, bone-targeting, and neuroendocrine research questions.
• Transparent milestone reporting and rapid scientific feedback throughout the engagement.

Contact Us

Ready to advance your late-stage prostate cancer program with a rigorously controlled orthotopic platform? Alfa Cytology invites you to reach out to us to scope your PC3 / PC3-luc study — share your targets and endpoints, and we will return a tailored design, timeline, and quotation. Contact us today to get started.

For research use only. Not intended for any clinical use.